2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Celebrating TB day at the time of COVID-19

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          March 24th, the tuberculosis (TB) day, is the global call to raise awareness, celebrate successes and remind the world that TB is still the N°1 killer among the infectious causes of death [1]. TB is preventable and curable disease, and its control is a highly cost-effective health intervention. However, diagnostic delay and inadequate treatment contribute to the severity and mortality of the disease as well as the risk of transmission and development of drug resistance. Despite the fact that TB disproportionately impacts low- and middle- income countries, it does not spare any country in the world including those in the European Union/European Economic Area where more than 4000 of people still die for the disease every year [2]. Moreover, the high number of multidrug-resistant (MDR)-TB cases in some countries of the World Health Organization (WHO) European Region poses a growing public health threat. Despite the sheer numbers, TB has for too long been overshadowed by HIV and malaria, and currently by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 (COVID-19) epidemic.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A pneumonia outbreak associated with a new coronavirus of probable bat origin

          Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations

            Health care-associated infections (HAI) are a major public health problem with a significant impact on morbidity, mortality and quality of life. They represent also an important economic burden to health systems worldwide. However, a large proportion of HAI are preventable through effective infection prevention and control (IPC) measures. Improvements in IPC at the national and facility level are critical for the successful containment of antimicrobial resistance and the prevention of HAI, including outbreaks of highly transmissible diseases through high quality care within the context of universal health coverage. Given the limited availability of IPC evidence-based guidance and standards, the World Health Organization (WHO) decided to prioritize the development of global recommendations on the core components of effective IPC programmes both at the national and acute health care facility level, based on systematic literature reviews and expert consensus. The aim of the guideline development process was to identify the evidence and evaluate its quality, consider patient values and preferences, resource implications, and the feasibility and acceptability of the recommendations. As a result, 11 recommendations and three good practice statements are presented here, including a summary of the supporting evidence, and form the substance of a new WHO IPC guideline. Electronic supplementary material The online version of this article (doi:10.1186/s13756-016-0149-9) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19: too little, too late?

              The Lancet (2020)
              Although WHO has yet to call the outbreak of SARS-CoV-2 infection a pandemic, it has confirmed that the virus is likely to spread to most, if not all, countries. Regardless of terminology, this latest coronavirus epidemic is now seeing larger increases in cases outside China. As of March 3, more than 90 000 confirmed cases of COVID-19 have been reported in 73 countries. The outbreak in northern Italy, which has seen 11 towns officially locked down and residents threatened with imprisonment if they try to leave, shocked European political leaders. Their shock turned to horror as they saw Italy become the epicentre for further spread across the continent. As the window for global containment closes, health ministers are scrambling to implement appropriate measures to delay spread of the virus. But their actions have been slow and insufficient. There is now a real danger that countries have done too little, too late to contain the epidemic. By striking contrast, the WHO-China joint mission report calls China's vigorous public health measures toward this new coronavirus probably the most “ambitious, agile and aggressive disease containment effort in history”. China seems to have avoided a substantial number of cases and fatalities, although there have been severe effects on the nation's economy. In its report on the joint mission, WHO recommends that countries activate the highest level of national response management protocols to ensure the all-of-government and all-of-society approaches needed to contain viral spread. China's success rests largely with a strong administrative system that it can mobilise in times of threat, combined with the ready agreement of the Chinese people to obey stringent public health procedures. Although other nations lack China's command-and-control political economy, there are important lessons that presidents and prime ministers can learn from China's experience. The signs are that those lessons have not been learned. SARS-CoV-2 presents different challenges to high-income and low-income or middle-income countries (LMICs). A major fear over global spread is how weak health systems will cope. Some countries, such as Nigeria, have so far successfully dealt with individual cases. But large outbreaks could easily overwhelm LMIC health services. The difficult truth is that countries in most of sub-Saharan Africa, for example, are not prepared for an epidemic of coronavirus. And nor are many nations across Latin America and the Middle East. Public health measures, such as surveillance, exhaustive contact tracing, social distancing, travel restrictions, educating the public on hand hygiene, ensuring flu vaccinations for the frail and immunocompromised, and postponing non-essential operations and services will all play their part in delaying the spread of infection and dispersing pressure on hospitals. Individual governments will need to decide where they draw the line on implementing these measures. They will have to weigh the ethical, social, and economic risks versus proven health benefits. The evidence surely indicates that political leaders should be moving faster and more aggressively. As Xiaobo Yang and colleagues have shown, the mortality of critically ill patients with SARS-CoV-2 pneumonia is substantial. As they wrote recently in The Lancet Respiratory Medicine, “The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced.” This coronavirus is not benign. It kills. The political response to the epidemic should therefore reflect the national security threat that SARS-CoV-2 represents. National governments have all released guidance for health-care professionals, but published advice alone is insufficient. Guidance on how to manage patients with COVID-19 must be delivered urgently to health-care workers in the form of workshops, online teaching, smart phone engagement, and peer-to-peer education. Equipment such as personal protective equipment, ventilators, oxygen, and testing kits must be made available and supply chains strengthened. The European Centre for Disease Prevention and Control recommends that hospitals set up a core team including hospital management, an infection control team member, an infectious disease expert, and specialists representing the intensive care unit and accident and emergency departments. So far, evidence suggests that the colossal public health efforts of the Chinese Government have saved thousands of lives. High-income countries, now facing their own outbreaks, must take reasoned risks and act more decisively. They must abandon their fears of the negative short-term public and economic consequences that may follow from restricting public freedoms as part of more assertive infection control measures. © 2020 Manuel Silvestri/Reuters Picutres 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
                Bookmark

                Author and article information

                Journal
                Eur Respir J
                Eur. Respir. J
                ERJ
                erj
                The European Respiratory Journal
                European Respiratory Society
                0903-1936
                1399-3003
                02 April 2020
                : 2000650
                Affiliations
                [1 ]IRCCS San Raffaele Scientific Institute, Milan, Italy
                [2 ]StopTB Italia Onlus, Milan, Italy
                [3 ]Regional TB Reference Centre, Istituto Villa Marelli, Ospedale Niguarda, Milan, Italy
                [4 ]Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milano, Italy
                [5 ]Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy
                [6 ]Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Varese , Italy
                [7 ]Global Health Centre, University of Milan, Milan, Italy
                Author notes
                Daniela Maria Cirillo, IRCCS San Raffaele Scientific Institute, Milan, Italy. E-mail: cirillo.daniela@ 123456hsr.it
                Author information
                https://orcid.org/0000-0002-2597-574X
                https://orcid.org/0000-0001-6415-1535
                Article
                ERJ-00650-2020
                10.1183/13993003.00650-2020
                7113797
                32241828
                a3e81432-8d5b-4008-881b-f117c12eb7ed
                Copyright ©ERS 2020

                This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

                History
                : 11 March 2020
                : 24 March 2020
                Categories
                Research Letter

                Respiratory medicine
                Respiratory medicine

                Comments

                Comment on this article